Arvinas

IPO

Targeted Protein Degradation Therapeutics

Arvinas is a biotech company in New Haven, United States, founded in 2013. It has raised $465.9M across 5 rounds, most recently a $350.0M Private Equity in November 2023.

Employees
201–500
Founded
2013
Business Model
B2B
Total Funding
$465.9M
Last Round
$350.0M Private EquityNov 2023
Rounds
5
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 5 funding rounds and 14 investors for this company. to use credits for reveals, or explore the API.

About

Arvinas is a clinical-stage biopharmaceutical company and pioneer of PROTAC protein degrader technology, harnessing the body's own ubiquitin-proteasome system to selectively degrade disease-causing proteins. Its pipeline spans oncology and neurology, with lead programs targeting the androgen receptor (ARV-110) and estrogen receptor (ARV-471) in partnership with Pfizer. The company's platform addresses historically undruggable targets, offering potential advantages over traditional inhibitor approaches.

Funding & Exit History

Data from Indexed.vcUpdated
Private EquityPrivate PlacementNov 2023
$350.0M

5 more events

  • IPO20181 investor
  • Series C20189 investors
  • Grant2016

Funding: Series A through Private Equity. Amounts, valuations, and investors where available.

Investors

Tech & App Stack

7 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

  • Backend ×2
  • Frontend ×2
  • DevOps ×1
  • Marketing & SEO ×1
  • Other ×1

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Companies in related industries

Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Biotech
Series ATotal funding$3.0BJan 2022
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech
Growth EquityTotal funding$2.7BJul 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech
Private EquityTotal funding$2.3BFeb 2020
Calico

Calico researches human aging using advanced technologies and model systems, applying that knowle...

South San Francisco, United States201–500Biotech
Corporate RoundTotal funding$2.3BJun 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech
Series DTotal funding$1.4BJun 2020
CertaraIPO

Global biosimulation software and services company accelerating drug development for 2,000+ bioph...

Radnor, United States1001–5000Biotech
Private EquityTotal funding$1.3BDec 2022

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Arvinas on Indexed.vc
<a href="https://indexed.vc/companies/arvinas"><img src="https://indexed.vc/api/badge/company/arvinas" alt="Arvinas on Indexed.vc" width="260" height="76" /></a>